# A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant

> **NCT07092865** · PHASE2 · RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 184 (estimated)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **BIOLOGICAL:** Adjuvanted RSVPreF3 vaccine

## Key facts

- **NCT ID:** NCT07092865
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-06
- **Primary completion:** 2027-01-12
- **Final completion:** 2027-07-16
- **Target enrollment:** 184 (ESTIMATED)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07092865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07092865, "A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07092865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*